Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUN4936c Phase 2 trial for prevention of contrast-induced nephropathy
jRCT1091220379Phase 2Recruiting
- Sponsor
- Yoshihiko Saito
- Start
- Aug 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of carperitide in contrast-induced nephropathy (CIN), acute kidney failure (AKF) and chronic kidney disease (CKD) (4 arms), sponsored by Yoshihiko Saito. Primary endpoint: Incidence of contrast-induced nephropathy. Started Aug 2018; status: recruiting.
02
Drugs
carperitide
03
Conditions
contrast-induced nephropathy (CIN)acute kidney failure (AKF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT1091220379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1091220379.